Price T Rowe Associates Inc. MD Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Price T Rowe Associates Inc. MD grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 596.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,109,978 shares of the company's stock after buying an additional 950,557 shares during the period. Price T Rowe Associates Inc. MD owned 2.12% of Janux Therapeutics worth $59,429,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares during the period. Rhumbline Advisers lifted its stake in Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after purchasing an additional 599 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Janux Therapeutics by 7.9% in the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock worth $681,000 after buying an additional 928 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock valued at $926,000 after acquiring an additional 949 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Janux Therapeutics by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after purchasing an additional 1,095 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 341,742 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,335 shares of company stock valued at $454,959. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Stock Up 2.6 %

Shares of JANX stock traded up $0.83 on Friday, hitting $32.88. The stock had a trading volume of 825,257 shares, compared to its average volume of 847,327. Janux Therapeutics, Inc. has a one year low of $22.52 and a one year high of $71.71. The business has a 50 day moving average price of $29.80 and a 200 day moving average price of $42.47. The company has a market cap of $1.95 billion, a PE ratio of -28.10 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Finally, Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.